The company said that the patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities. The product has been developed as an alternative to the legacy Staphylococcus aureus Protein A, and will be the basis of Repligen’s future chromatography product development.
Walter Herlihy, president and CEO of Repligen, said: “This action by the patent office reflects our continuing investment and commitment to our Bioprocessing business. This recently launched recombinant Protein A product is an important step in expanding our business through both organic growth and product acquisition.”
Repligen is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.